Envoy Medical, Inc. 8-K

What Happened

• Envoy Medical, Inc. announced that on April 15, 2026 the Board appointed Charles S. McKhann as a Class I director, increasing the Board from six to seven members. His initial term expires at the Company’s 2027 annual meeting of stockholders. He was also appointed to the Board’s Compensation Committee and has been determined to be an independent director under Nasdaq and SEC standards.
• Mr. McKhann currently serves as a director of Exagen, Inc. and as Executive Chairman at Distalmotion SA, and previously held executive roles at Silk Road Medical, Apollo Endosurgery, ROX Medical, Torax Medical and Intersect ENT. He holds a B.A. in Political Science and an M.B.A. from Stanford University.

Key Details

• Appointment effective: April 15, 2026; initial term ends at 2027 annual meeting.
• Board size: increased from six members to seven members.
• Compensation: granted options to purchase 100,000 shares of Class A common stock at $0.72 per share; vesting over 36 equal monthly installments.
• Governance: joined the Compensation Committee; Board deemed him independent; he signed the Company’s standard director indemnification agreement. No related-person transactions reported under Item 404.

Why It Matters

• The addition brings an experienced medical-device executive to Envoy’s Board, potentially adding commercial and M&A experience given his prior CEO roles and involvement in companies acquired by Boston Scientific.
• His seat on the Compensation Committee and independent status affect board oversight of executive pay and governance. The option grant is a standard director equity incentive and dilutive impact is limited (100,000 shares at strike $0.72).
• For investors, this is a governance and leadership update — not a financial result — that could influence strategic oversight and management accountability going forward.